Cargando…

Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis

OBJECTIVE: The IL-23 p19-subunit inhibitor guselkumab has been previously compared with other targeted therapies for PsA through network meta-analysis (NMA). The objective of this NMA update was to include new guselkumab COSMOS trial data, and two key comparators: the IL-23 inhibitor risankizumab an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mease, Philip J, McInnes, Iain B, Tam, Lai-Shan, Rajalingam, Raji, Peterson, Steve, Hassan, Fareen, Chakravarty, Soumya D, Contré, Christine, Armstrong, Alison, Boehncke, Wolf-Henning, Ritchlin, Christopher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Systematic Review and Meta Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070072/ https://www.ncbi.nlm.nih.gov/pubmed/36102818 http://dx.doi.org/10.1093/rheumatology/keac500

Ejemplares similares

Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis
por: Mease, Philip J, et al.
Publicado: (2021)

Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies
por: Ritchlin, Christopher T, et al.
Publicado: (2022)

Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies
por: McGonagle, Dennis, et al.
Publicado: (2023)

Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies
por: McGonagle, Dennis, et al.
Publicado: (2021)

Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial
por: Helliwell, Philip S., et al.
Publicado: (2020)

Efficacy and Safety of Guselkumab, an Interleukin‐23p19–Specific Monoclonal Antibody, Through One Year in Biologic‐Naive Patients With Psoriatic Arthritis
por: McInnes, Iain B., et al.
Publicado: (2021)

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2022)

Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2022)

Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis
por: Gottlieb, Alice B, et al.
Publicado: (2023)

Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
por: Mease, Philip, et al.
Publicado: (2016)

Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2023)

Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 Study
por: Ritchlin, Christopher T., et al.
Publicado: (2023)

Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review
por: Vincken, Nanette L A, et al.
Publicado: (2022)

Guselkumab: widened action in psoriatic disease
por: Arnone, Marcelo, et al.
Publicado: (2021)

Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis
por: McInnes, Iain B., et al.
Publicado: (2022)

Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis
por: Orbai, Ana-Maria, et al.
Publicado: (2023)

Comparative risk of herpes zoster in patients with psoriatic disease on systemic treatments: a systematic review and network meta-analysis
por: Chiu, Hsien-Yi, et al.
Publicado: (2022)

Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study
por: Mease, Philip J, et al.
Publicado: (2020)

Systematic literature review of non-topical treatments for early, untreated (systemic therapy naïve) psoriatic disease: a GRAPPA initiative
por: De Marco, Gabriele, et al.
Publicado: (2020)

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced
por: Ritchlin, Christopher T, et al.
Publicado: (2021)

Do Patients with Psoriatic Arthritis Have More Severe Skin Disease than Patients with Psoriasis Only? A Systematic Review and Meta-Analysis
por: Pouw, Juliëtte N., et al.
Publicado: (2022)

Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
por: Mease, Philip J., et al.
Publicado: (2023)

Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials
por: Sweet, Kristen, et al.
Publicado: (2021)

Comparative short-term risks of infection and serious infection in patients receiving biologic and small-molecule therapies for psoriasis and psoriatic arthritis: a systemic review and network meta-analysis of randomized controlled trials
por: Chiu, Hsien-Yi, et al.
Publicado: (2023)

Teledermatology in the COVID-19 pandemic: A systematic review
por: Loh, Chee Hoou, et al.
Publicado: (2021)

Paradoxical psoriatic arthritis flare with the initiation of brodalumab and guselkumab
por: Kashlan, Reem, et al.
Publicado: (2021)

Guselkumab-induced vitiligo in a patient with psoriatic arthritis
por: Martora, Fabrizio, et al.
Publicado: (2023)

The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial
por: Ritchlin, Christopher T., et al.
Publicado: (2023)

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study
por: McInnes, Iain B, et al.
Publicado: (2017)

Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
por: Gladman, Dafna D., et al.
Publicado: (2022)

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)
por: Nash, Peter, et al.
Publicado: (2018)

Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials
por: Mease, Philip J, et al.
Publicado: (2021)

Role of the halo sign in the assessment of giant cell arteritis: a systematic review and meta-analysis
por: Sebastian, Alwin, et al.
Publicado: (2021)

Synovial Tissue Response to Treatment in Psoriatic Arthritis
por: Codullo, Veronica, et al.
Publicado: (2011)

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
por: Coates, Laura C, et al.
Publicado: (2022)

Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2
por: McInnes, Iain B, et al.
Publicado: (2019)

Neurocognitive outcomes in pediatric brain tumors after treatment with proton versus photon radiation: a systematic review and meta-analysis
por: Lassaletta, Álvaro, et al.
Publicado: (2023)

A meta-analysis on Omega-3 supplements in preventing recurrence of atrial fibrillation
por: Jiang, Ying, et al.
Publicado: (2017)

Personal protective equipment-related occupational dermatoses during COVID-19 among health care workers: A worldwide systematic review
por: Keng, Bryan M.H., et al.
Publicado: (2021)

Effects and safety of natriuretic peptides as treatment of cirrhotic ascites: A systematic review and meta-analysis
por: Gantzel, Rasmus Hvidbjerg, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rfjvngjb0ush7nc9eicth9t1fm